Showing results (271-280 of 352) with videos related to
Sort By:
Pageof 36
Journal of the American Academy of Dermatology|April 29, 2005
Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studiesAmy S Paller, Mark Lebwohl, Alan B Fleischer, et al.Lancet (London, England)|May 20, 2008
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)Kim A Papp, Richard G Langley, Mark Lebwohl, et al.Photochemistry and Photobiology|February 6, 2008
p53 gene mutations in SKH-1 mouse tumors differentially induced by UVB and combined subcarcinogenic benzo[a]pyrene and UVAYongyin Wang, Xueyan Zhou, Elhav Weinstein, et al.Journal of Drugs in Dermatology : JDD|May 4, 2026
Efficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus PanelBrooke Bartley, Angela Rosenberg, Lauren DeBusk, et al.The New England Journal of Medicine|April 23, 2021
Bimekizumab versus Secukinumab in Plaque PsoriasisKristian Reich, Richard B Warren, Mark Lebwohl, et al.Clinical and Experimental Dermatology|May 24, 2025
Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasisMark Lebwohl, Melinda J Gooderham, Richard B Warren, et al.Journal of Drugs in Dermatology : JDD|August 3, 2007
Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studiesMark Lebwohl, Alan Menter, Jonathan Weiss, et al.Journal of Drugs in Dermatology : JDD|August 2, 2024
Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus PanelJoshua Burshtein, Milaan Shah, Danny Zakria, et al.Journal of the American Academy of Dermatology|December 20, 2023
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasisAndrew Blauvelt, Phoebe Rich, Howard Sofen, et al.Dermatology Online Journal|February 23, 2026
31-Gene expression profiling for cutaneous melanoma: an expert consensus panelJoshua Burshtein, Clay Cockerell, David Cotter, et al.Pageof 36